Mirtazapine

Mirtazapine, the active ingredient in Mirtazapine, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is prescribed to alleviate symptoms of major depressive disorder in adult patients and may be used as part of a comprehensive treatment plan that includes psychotherapy.

GNH USA supplies Mirtazapine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch, ensuring reliable and traceable supply.

Mirtazapine is a tetracyclic antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Depressive episodes in bipolar disorder: used as an adjunct to stabilize mood when other agents are insufficient. - Treatment‑resistant depression: considered when first‑line antidepressants have not achieved adequate response.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Anaphylactic or severe allergic reactions - Serotonin syndrome, especially with other serotonergic agents - Suicidal thoughts or worsening depression - Hepatic dysfunction or jaundice

Before initiating therapy, clinicians should evaluate specific risk factors and monitor patients closely.

- Assess psychiatric history: monitor for worsening depression or emergent suicidal ideation. - Evaluate hepatic function: consider dose adjustment in severe liver impairment. - Caution in elderly: increased risk of sedation, falls and orthostatic changes. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal symptoms. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis or serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma concentrations.

Moderate Interactions (Monitor Closely): - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation. - Anticholinergic agents: increased anticholinergic burden. - Warfarin: potential alteration of INR, requiring coagulation monitoring.